Price Target Changes｜Lucid Reduced to $36 by Citi; Virgin Galactic Lowered to $8 by Truist Securities
Benzinga2022-05-09
- Morgan Stanley cut Guardant Health, Inc. price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.
- Oppenheimer cut the price target for Relmada Therapeutics, Inc. from $75 to $64. Relmada Therapeutics shares fell 5.2% to close at $21.23 on Friday.
- Mizuho raised the price target on McKesson Corporation from $280 to $331. McKesson shares fell 0.8% to $331.36 in pre-market trading.
- Credit Suisse boosted the price target for Kellogg Company from $62 to $69. Kellogg shares fell 1.4% to $71.70 in pre-market trading.
- Barclays boosted the price target on EPAM Systems, Inc. from $350 to $410. EPAM Systems shares fell 3.7% to $334.03 in pre-market trading.
- Wells Fargo raised the price target on Cigna Corporation from $278 to $306. Cigna shares fell 0.7% to $265.00 in pre-market trading.
- Citigroup reduced Lucid Group, Inc. price target from $45 to $36. Lucid Group shares fell 4% to $17.42 in pre-market trading.
- Truist Securities reduced Virgin Galactic Holdings, Inc. price target from $24 to $8. Virgin Galactic shares fell 3.9% to $6.53 in pre-market trading.
- JMP Securities cut Intellia Therapeutics, Inc. price target from $165 to $110. Intellia Therapeutics shares dropped 5.2% to $45.07 in pre-market trading.
- Telsey Advisory Group lowered Under Armour, Inc. price target from $25 to $17. Under Armour shares fell 1% to $10.78 in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
